Northeast Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Northeast Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,010	Closed	-$215K	–	159
2016 Q1	$215K	Buy	4,010 +163	+4%	+$9.56K	0.02%	149
2015 Q4	$253K	Hold	3,847	–	–	0.03%	133
2015 Q3	$217K	Buy	3,847 +185	+5%	+$12K	0.02%	150
2015 Q2	$216K	Sell	3,662 -75	-2%	-$4.63K	0.02%	150
2015 Q1	$233K	Hold	3,737	–	–	0.02%	152
2014 Q4	$215K	Sell	3,737 -38	-1%	-$2.12K	0.02%	163
2014 Q3	$203K	Buy	+3,775	New	+$200K	0.02%	174
2014 Q2	–	Sell	-3,820	Closed	-$202K	–	180
2014 Q1	$202K	Buy	+3,820	New	+$177K	0.02%	166
2013 Q4	–	Sell	-5,867	Closed	-$222K	–	171
2013 Q3	$222K	Sell	5,867 -76	-1%	-$2.96K	0.03%	150
2013 Q2	$233K	Buy	+5,943	New	+$231K	0.03%	140

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northeast Investment Management's TEVA Position: Q2 2016 in Review

Northeast Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 4,010 shares — an estimated $215K sold.

Northeast Investment Management first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $253K in Q4 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Northeast Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Northeast Investment Management sold 4,010 Teva Pharmaceuticals shares in Q2 2016, an estimated $215K.
Northeast Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Northeast Investment Management's Teva Pharmaceuticals position peaked at $253K in Q4 2015.
813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Northeast Investment Management's 13F filing for Q2 2016, filed 2 Aug 2016.